BELLICUM PHARMACEUTICALS, INC 4
4 · BELLICUM PHARMACEUTICALS, INC · Filed Jul 12, 2017
Insider Transaction Report
Form 4
Spencer David M.
Chief Scientific Officer
Transactions
- Sale
Common Stock
2017-07-10$11.54/sh−10,000$115,400→ 138,965 total
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 22, 2017 by the Reporting Person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.50 to $11.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]Includes 946 shares and 1,937 shares acquired by the Reporting Person under the Issuer's 2014 Employee Stock Purchase Plan on December 9, 2016 and June 10, 2017, respectively.